Trial report in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03909724 (A Randomized Phase II Study of Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03909724 phase2 / phase3unknown statusnot on this map
A Randomized Phase II Study of Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
TypeinterventionalSponsorAmsterdam UMC, location VUmcRan2019 to 2022Enrolled60ConditionsColorectal Cancer, MetastasisArmsSunitinib Malate, TAS 102
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Jorien B E JanssenDepartment of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0001-9190-9911
Kirti K IyerDepartment of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0003-1146-5009
Sophie L GerritseDepartment of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0002-6287-4016
Eline JanssenDepartment of Medical Biosciences, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0002-7407-2424
Elske C GootjesDepartment of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0009-0000-9898-2767
Mariette LabotsDepartment of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam 1081HV, The Netherlands.ORCID 0000-0002-7095-1771
Tineke E BuffartDepartment of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam 1081HV, The Netherlands.ORCID 0000-0003-2464-7741
Miriam L WumkesDepartment of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, 5223GZ The Netherlands.
Joeri A J DoumaDepartment of Gastroenterology, Netherlands Cancer Institute, Amsterdam, 1066CX The Netherlands.
Mirte M StreppelDepartment of Medical Oncology, Amphia Hospital, Breda, 4818CK The Netherlands.
Laurien M BuffartDepartment of Medical Biosciences, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0002-8095-436X
Marianne A JonkerDepartment for IQ Health, section Biostatistics, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0003-0134-8482
Erik van den HomberghDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0009-0005-8494-4424
Nielka P van ErpDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0003-1553-178X
Jan Paul MedemaLaboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam 1081BT, The Netherlands.ORCID 0000-0003-3045-2924
Daniele V F TaurielloDepartment of Medical Biosciences, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0003-1522-3496
Dennis PoelDepartment of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0002-4395-2824
Henk M W VerheulDepartment of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.ORCID 0000-0001-5981-922X
Funding
ZonMw 446002901
6 · The paper itself
Abstract
backgroundPatients with metastatic colorectal cancer often have poor or short responses to currently available therapies. Drug repurposing with alternative dosing schedules may offer unexpected clinical benefit, even for agents that previously failed for this indication.
methodsWe explored a high-dose treatment strategy for sunitinib, assessing its potential for both cancer cell killing and inducing immunogenic cell death in patient-derived tumor organoids (PDTOs) of metastatic colorectal cancer (mCRC). In a randomized clinical trial, we studied the efficacy of high-dose intermittent sunitinib (700 mg once every 2 weeks) in patients with advanced CRC compared to standard therapy with trifluridine/tipiracil. The primary outcome measure was progression-free survival (PFS); secondary outcomes included overall survival, safety and tolerability, quality of life, and exploratory biomarker analyses.
resultsWhile high, intermittent dosing was found to effectively kill PDTOs in vitro, no support for immunogenic cell death was found. In our clinical trial, among a total of 63 evaluable patients, median PFS was 2.8 months (95% CI 0.9-4.7) for the investigation arm compared to 1.9 months (95% CI 1.6-2.3) for the trifluridine/tipiracil group (P = .78, HR 1.22; 95% CI 0.73-2.04). The trial was halted prematurely due to toxicities: in particular, hemorrhage, fever and gastrointestinal adverse events.
conclusionHigh-dose intermittent sunitinib treatment did not improve PFS for patients with heavily pretreated mCRC compared to standard 3rd or 4th-line treatment with trifluridine/tipiracil, whereas significant toxicity was observed. In addition, this approach provoked no relevant immunological responses in vitro, discouraging further research for potential combinations with immunotherapeutics. IDENTIFIER: NCT03909724.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. · full record | OpenQuestion